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Abstract
Objectives: We assessed the current genetic evidence for the involvement of
various cell types and tissue types in the etiology of neurodegenerative diseases,
especially in relation to the neuroinflammatory hypothesis of neurodegenerative
diseases. Methods: We obtained large-scale genome-wide association study
(GWAS) summary statistics from Parkinson’s disease (PD), Alzheimer’s disease
(AD), and amyotrophic lateral sclerosis (ALS). We used multiple sclerosis
(MS), an autoimmune disease of the central nervous system, as a positive con-
trol. We applied stratified LD score regression to determine if functional marks
for cell type and tissue activity, and gene-set lists were enriched for genetic heri-
tability. We compared our results to those from two gene-set enrichment meth-
ods (Ingenuity Pathway Analysis and enrichr). Results: There were no
significant heritability enrichments for annotations marking genes active within
brain regions, but there were significant heritability enrichments for annotations
marking genes active within cell types that form part of both the innate and
adaptive immune systems. We found this for MS (as expected) and also for AD
and PD. The strongest signals were from the adaptive immune system (e.g., T
cells) for PD, and from both the adaptive (e.g., T cells) and innate (e.g., CD14:
a marker for monocytes, and CD15: a marker for neutrophils) immune systems
for AD. Annotations from the liver were also significant for AD. Pathway analy-
sis provided complementary results. Interpretation: For AD and PD, we found
significant enrichment of heritability in annotations marking gene activity in
immune cells.
Introduction
Neurodegenerative diseases – including Alzheimer’s (AD),
amyotrophic lateral sclerosis (ALS), and Parkinson’s
disease (PD) – are personally devastating and an increas-
ing burden on health care systems worldwide. Recently
there has been much progress in identifying genetic vari-
ants associated with neurodegenerative diseases. In the
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latest AD meta-analysis, 19 loci in addition to the well-
established APOE locus were pinpointed.1 The latest ALS
meta-analysis identified three ALS-associated loci2 and the
latest PD meta-analysis brought the total number of
established PD loci to 26.3 Despite progress in identifying
genetic hits in these neurodegenerative diseases, the
underlying processes or cell types mediating the pathology
remain uncertain.
As genome-wide association studies (GWASs) have
grown in size and power, so has the quality and scope of
functional information that can be used to annotate the
genome with relevant genomic and epigenomic marks
linked to the regulation of gene expression. Previous stud-
ies have demonstrated enrichment of disease-associated
variants (for numerous diseases) with functional genomic
annotations, including DNase I hypersensitive sites, tran-
scription factor binding sites, histone modifications, and
expression quantitative trait loci (eQTLs).4–7 These anno-
tations vary depending on cell/tissue type. Given the
many ways in which complex diseases arise, and for
human brain diseases, the well-recognized cellular hetero-
geneity of the brain, pinpointing cell types of interest, is
important to further understand pathogenicity. Efforts to
obtain brain samples (the most obviously relevant tissue
for neurodegenerative diseases) for eQTL analyses are
ongoing.8–13 There has been a recent proliferation in the
availability of cell-type and tissue-specific annotations,
including brain tissue, for example, through the Roadmap
Epigenomics Project14 and the PsychEncode Project.11
Nevertheless, obtaining large numbers of post mortem
human brains remains challenging, and current eQTL
analyses are likely to be underpowered. Characterization
of eQTLs and DNA regulatory elements in blood is a
complementary approach.
The neuroinflammatory hypothesis of neurodegenera-
tive diseases posits that dysregulation of the immune sys-
tem is an important factor in the etiology of these
diseases.15,16 There is little doubt that multiple sclerosis
(MS) is an immune-mediated disease.17–19 We therefore
use this disease as a positive control with regard to
expected enrichment in heritability for annotations from
immune cells. There is extensive functional and clinical
evidence that immune dysfunction plays a key role in the
pathogenesis of the relapse-remitting phase of MS.20,21
For AD, Yokoyama et al.22 showed that eight variants
were associated with both AD and immune-mediated dis-
eases, and there is further evidence from pathway analy-
sis1,23,24 and from animal models.25 For PD, the role of
the immune system has been suggested through pathway
analyses,26,27 animal models,28 and variants in the Human
Leukocyte Antigen (HLA) region reaching statistical sig-
nificance in GWASs.3,29 For ALS, there is evidence of
immune abnormalities.30 Nevertheless, the extent to
which the immune system is involved in neurodegenera-
tive diseases, such as AD, ALS and PD, and the potential
roles played by the innate and adaptive immune compo-
nents remain unestablished.
Finucane et al.31 introduced stratified LD score regres-
sion as a method for partitioning the inferred heritability
from GWAS summary statistics. They determined whether
genetic heritability in 17 GWASs was enriched within var-
ious functional annotations which reflected parts of the
genome that were active in a number of tissues and cell
types. We applied this methodology to four diseases (MS,
AD, ALS, PD) to test for enrichment of heritability, both
using Finucane et al.’s31 cell-type group annotations and
using additional annotations from brain and immune
cells and from published sets of brain and immune-
related genes.32
Methods
We obtained GWAS summary statistics for three neu-
rodegenerative diseases: AD,1 ALS,2 and PD.3 We used
MS33 as a positive control, as it is a disease affecting the
brain with known immune etiology. All studies were con-
ducted in European populations, and are summarized in
Table 1. For AD, which is a two-stage study, we only
used data from the first stage (see Box 1 for details on
this study). We did not study Huntington’s disease
(which has other genetic modifiers in addition to the pri-
mary HTT locus) and frontotemporal dementia, because
the current GWAS sample sizes for these diseases are
modest, and thus the datasets were considered to be
insufficiently powered for our analyses.31
We estimated pairwise genetic correlations among the
four diseases using cross-trait LD score regression.34 We
then applied stratified LD score regression to determine if
various functional categories (cell-type groups, annota-
tions at the tissue/cell level for brain or immune cells,
and sets of brain and immune gene lists) were enriched
for heritability. LD score regression exploits the expected
relationships between true association signals and local
LD around them to correct out systematic biases and
Table 1. Description of the genome-wide association studies sum-
mary statistics.
Neurodegenerative
disease PMID Cases Controls Cohorts
Parkinson’s disease 25064009 13,708 95,282 15
Alzheimer’s disease 24162737 17,008 37,154 19
Amyotrophic lateral
sclerosis
24256812 7177 8393 8
Multiple sclerosis 21833088 9772 17,376 23
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arrive at unbiased estimates of genetic heritability within
a given set of SNPs (here stratified according to their
functional category).31 Following Finucane et al.,31 we
added annotations individually to the baseline model; we
used HapMap Project Phase 3 SNPs for the regression
and 1000 Genomes Project European population SNPs
for the reference panel; we only partitioned the heritabil-
ity of SNPs with minor allele frequency >5%; and we
excluded the Major Histocompatibility Complex (MHC)
region from analysis. The high LD and strong association
signals within the MHC region results in a dominating
effect on LD score regression, and for the purposes of our
analyses excluding this region result in a conservative
approach.
The grouped cell-type annotations provided by Finu-
cane et al.31 are the union of histone marks for 10 broad
categories including central nervous system (CNS), car-
diovascular, immune/hematopoietic, and liver. For these
analyses, we corrected for multiple testing of four GWASs
across 10 cell-type groups (4 9 10 = 40 hypotheses
tested), resulting in a Bonferroni significance threshold of
P = 1.2 9 103.
We then extended the analytical approach of Finucane
et al.31 in the following ways. First, we obtained additional
annotation information. We obtained histone marks and
DNase I hypersensitive sites data from the Roadmap
Epigenomics Consortium14; we obtained eQTLs derived
from brain regions from the UK Brain Expression Consor-
tium10 and the GTEx Consortium9; and we obtained pro-
moter capture HiC array express data in CD34 (a marker
of immature hematopoietic cells) cells from GM12878
(reference: E-MTAB-2323).35 We also considered two gene
sets. All these annotations are listed in Table S1. Second,
in order to reduce the multiple testing burden, we com-
bined information across the four different histone marks
and the DNase I hypersensitive marks in order to create
an aggregate set of regulatory marks for each cell type.
This aggregation annotation was obtained based on a sim-
ple union operation: for each tissue or cell type, a SNP
was labeled as “annotated” based on whether it possessed
any relevant histone mark or DNase I hypersensitive mark.
Both DNase I and histone marks are known to reflect
active regions of the genome, motivating their aggregation
in order to create a general mark of genomic activity.
DNase I sites are associated with an open chromatin struc-
ture, and different histone marks are markers of active
promoters (H3K4Me3 + H3K27Ac) or active enhancers
(H3K4Me1 + H3K27Ac) regions.
For brain tissue, we defined a union set of histone
marks plus DNase I hypersensitive sites from the Road-
map Epigenomics Consortium14 using the same aggrega-
tion procedure as above. This processing resulted in one
annotation per brain region (10 annotations).
We grouped eQTLs across all brain regions, but treated
the eQTLs from the UK Brain Expression Consortium10
and the GTEx Consortium9 separately (resulting in two
annotations). Both the GTEx and UKBEC analyses
included brain regions highly relevant to MS, AD, and
PD, namely white matter, hippocampus, temporal cortex,
and substantia nigra.
Among specific immune cells, we assessed the histone
marks described previously,31 and also the histone marks
and DNase I hypersensitive site data from the Roadmap
Epigenomics Consortium for immune and blood cells,14
and we took the union for each cell type as described
above (three histone marks and DNase I hypersensitive
site). This resulted in 20 annotations from Finucane
et al.31 and 14 annotations from Roadmap.
Additionally, we defined four immune cell-type
annotations based on promoter capture HiC array express
data in CD34 from GM12878 (reference: E-MTAB-
2323).35 The data for the prey and bait were analyzed sep-
arately for interactions between captured promoter and
captured promoter interactions and for captured
promoter and all other regions, which resulted in four
annotations.
The above cell/tissue-type-specific annotations resulted
in a multiple testing correction for four GWASs across 50
(12 brain + 38 immune) annotations (4 9 50 = 204
hypotheses tested). Thus, we set a Bonferroni significance
threshold of P = 2.5 9 104 for these analyses. Note that
there are correlations within the immune and brain anno-
tations, making our Bonferroni correction somewhat con-
servative.
Box 1.
International Genomics of Alzheimer’s Project (IGAP) is
a large two-stage study based on GWAS on individuals of
European ancestry. In stage 1, IGAP used genotyped and
imputed data on 7,055,881 single nucleotide polymor-
phisms (SNPs) to meta-analyze four previously pub-
lished GWAS datasets consisting of 17,008 AD cases and
37,154 controls (the European Alzheimer’s Disease
Initiative – EADI, the Alzheimer Disease Genetics
Consortium – ADGC, the Cohorts for Heart and Aging
Research in Genomic Epidemiology consortium –
CHARGE, the Genetic and Environmental Risk in AD
consortium – GERAD). In stage 2, 11,632 SNPs were
genotyped and tested for association in an independent
set of 8572 AD cases and 11,312 controls. Finally, a meta-
analysis was performed combining results from stages 1
and 2.
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We also applied heritability enrichment analysis to two
sets of genes: one with known brain and one with known
immune function. We used a brain gene list of 2635
genes described previously by Raychaudhuri et al.,36 and
an immune gene list of 973 genes described previously by
Pouget et al.32 Brain genes were defined as those fulfilling
any of the following criteria: preferential expression in the
brain compared to other tissues, “neural-activity” annota-
tion in panther, “learning” annotation in ingenuity, and
“synapse” annotation in gene ontology. Immune genes
were defined as those with an “immune response” anno-
tation in at least three of the following databases: Kyoto
Encyclopedia of Genes and Genomes, Gene Ontology,
Ingenuity, and Immunology Database and Analysis Portal.
SNPs were annotated to genes using a 50-kb window, and
a baseline list of all genes using this 50-kb window was
included in the model as described previously.32
Finally, we contrasted the above heritability enrichment
analyses with a complementary approach based on gene-
set enrichment analysis. We used Ingenuity Pathway
Analysis (IPA) (www.ingenuity.com) to identify pathway
enrichment among genes associated with different neuro-
logical traits for canonical pathways. Canonical pathways
are structured pathways. Data from the different pheno-
types were integrated and subjected to network analysis
via IPA to identify pathway enrichment. Enriched net-
works are ordered by log P-value, based on a Fisher
exact test P-value.37 For each disease, we included SNPs
with a P < 5 9 104, and excluded SNPs in the MHC
region due to the long stretches of LD in this region. We
also performed a pathway analysis looking at KEGG path-
ways using enrichr38,39 in order to compare results.
Results
There is limited evidence of pairwise genetic correlation
among the four diseases using cross-trait LD score regres-
sion. The lack of an AD–PD pairwise correlation has
already been reported, as well as between AD–MS and
PD–MS.40 We also found no statistically significant evi-
dence for genetic correlation between ALS–AD (0.2,
P = 0.08), ALS–PD (0.08, P = 0.01), and ALS–MS
(0.04, P = 0.7).
For the grouped cell-type analysis from Finucane
et al.,31 the most significant enrichment was seen for the
immune/hematopoietic category for MS (10.1, P = 3.8 9
1013), confirming the recognized role of the immune sys-
tem in this disease. This category was also significantly
enriched for heritability of AD (5.5, P = 2.4 9 107), in
addition to liver (10.5, P = 1.1 9 105), and these AD sig-
nals remained significant even after the removal of APOE
(chr19: 44,905,754–44,909,393) (5.5, P = 2.5 9 107 and
10.5, P = 1.1 9 105, respectively). For ALS and PD, there
were no significantly enriched functional categories
(Fig. 1).
At the tissue level, none of the enrichments were signif-
icant for the brain annotations. The most suggestive sig-
nal was for the inferior temporal region in AD (4.9,
P = 6.6 9 104).
For the cell-specific immune annotations assessed relat-
ing to both the innate and adaptive immune systems,
there was significant enrichment for MS heritability and
to a lesser extent for AD and PD. There was no enrich-
ment of heritability for ALS, the smallest dataset in our
study (Table S1, Fig. 2). Strong MS signals for heritability
enrichment were found in all immune cell categories,
including both adaptive and innate cell types. Significant
AD signals were found in all immune cell categories
except for the non-T cell/non-B cell component of the
adaptive immune system. For PD, only two annotations
passed the multiple testing threshold: primary T-helper
cells phorbol 12-myristate 13-acetate and ionomycin
(PMA-I) stimulated and primary T-regulatory cells from
peripheral blood (5.2 and 5.4, respectively, P = 0.0002 for
both), but several other immune annotations were sugges-
tive.
Consistent with previous applications of the LD score
regression method, we included the annotations separately
in the regression model. This means that enrichments in
innate immune cells could in principle be due to overlap
in annotation with adaptive immune cell types and vice
versa. To assess this issue, we determined the degree of
annotation overlap between all pairs of immune cell types
in our study (Table S2). We found the degree of overlap
between innate versus adaptive cells ranged from 0.06%
(for CD14: a marker for monocytes vs. CD20: a marker
of B lymphocytes) to 12% (for peripheral blood mononu-
clear primary cell vs. primary T cells from cord blood),
suggesting a large degree of independence between adap-
tive and innate cell marks. To further investigate this
issue, we carried out deeper analyses on a representative
adaptive cell type (primary T cells from cord blood) and
a representative innate cell type (CD15: a marker for neu-
trophils), both of which displayed strong heritability
enrichment signals in AD. The annotation overlap
between these two cell types was 6.7% (Table S2). When
we included both annotations simultaneously in the LD
score regression model, we found that both cell lines
remained significantly enriched for MS (22.0,
P = 7.4 9 1020 and 17.2, 2.3 9 105, respectively). Sim-
ilarly, for AD, both cell lines remained significantly
enriched (8.7, P = 1.7 9 107 and 14.3, P = 7.3 9 106,
respectively). Neither of these cell lines had reached sig-
nificance for PD or ALS in the models where they were
inputted separately, nor were they significant when
included simultaneously into the model. The enrichment
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results for primary T cells from cord blood and CD15
when included simultaneously in the model for PD are
4.9, P = 1.1 9 103 and 7.0, P = 5.2 9 103, respec-
tively; and for ALS are 3.5, P = 0.03 and 3.1, P = 0.37,
respectively. Overall, these analyses provided us with reas-
surance that we were detecting independent signals in
adaptive versus innate immune cell types.
Our heritability enrichment analysis within brain-
related and immune-related gene sets also provided
strong evidence for a signal in the immune gene set, and
not in the brain gene set (Table S1). As expected, the
strongest immune gene signal was for MS (1.6,
P = 4.6 9 1014). We have previously reported the
enrichment of this immune gene list in the same MS
dataset, using an earlier version of LD score regression.32
The immune gene list was also enriched for heritability in
AD (5.2, P = 4.8 9 104), and the effects in PD and ALS
were suggestive but would not survive multiple testing
correction (4.5, P = 0.02 and 2.5, P = 0.03, respectively).
The brain gene list was not significantly enriched in any
Figure 1. Enrichment of cell-type groups as used in Finucane et al.31 The black dashed lines at log10(P) = 2.9 are the cutoff for Bonferroni
significance.
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of the neurodegenerative diseases assessed (among the
other three diseases enrichment ranges from 0.9 to 1.9,
P > 0.04 for all three).
Finally, we compared the above results to an IPA path-
way enrichment analysis, both within canonical pathways
(Table S3A) and within diseases/biological functions
including cancer-related functions (Table S3B). We also
compared our results to an enrichr pathway enrichment
analysis (Table S3C). Remarkably, for the IPA canonical
pathway analysis, all the significant pathways save one
(“Aldosterone Signaling in Epithelial Cells”) were found
to be connected to either adaptive or innate immune
response. Specific examples included: in MS (e.g.,
T-helper cell differentiation, role of macrophages, fibrob-
lasts, and endothelial cells in RA, B cell receptor signaling,
dendritic cell maturation, PI3K signaling in B lympho-
cytes, CD40 signaling; PKCh signaling in T lymphocytes,
NF-jB activation by viruses); in PD (e.g., dendritic cell
Figure 2. Enrichment of immune cell annotations. The black dashed lines at log10(P) = 3.6 are the cutoff for Bonferroni significance. White
bars = tissue; purple bars = CD34 (marker of immature hematopoietic cells – not strictly adaptive or innate); light blue bars = marker of T cells;
dark blue bar = marker of B cells; royal blue bars = cells of the adaptive immune system; pink bars = cells of the innate immune system.
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maturation – shared with MS, graft-versus-host disease
signaling, altered T cell and B cell signaling in rheumatoid
arthritis); in AD (IL-8 signaling, IL-12 signaling and pro-
duction in macrophages, Fc epsilon RI signaling, Fcc
receptor-mediated phagocytosis in macrophages and
monocytes, role of pattern recognition receptors in recog-
nition of bacteria and viruses, natural killer cell signaling);
and in ALS (e.g., NF-jB signaling). The value of the IPA
method was also demonstrated in providing significant
signals for other pathways previously implicated in the
pathogenesis of AD, including CREB signaling in neu-
rons,41 neuregulin signaling, and ErbB signaling.42 For the
IPA diseases/biological functions analysis, various cancers
came up as most strongly significant for all the disorders.
Cancer has been shown to be correlated with multiple
immune disorders,43 and there is evidence of cancer and
neurodegenerative disorders, such as PD, sharing com-
mon pathways.44 The enrichr analysis revealed many sig-
nificant immune-related pathways, in line with the IPA
canonical pathways analysis.
Discussion
Multiple lines of evidence suggest a significant contribu-
tion of variants exhibiting functional marks for chromatin
accessibility (i.e., histone marks, DNase I hypersensitive
sites) in immune cell types to the heritability of two neu-
rodegenerative diseases, namely AD and PD. Annotations
from immune cells are most significantly enriched for the
heritability of MS, a known autoimmune disease which
acted as a positive control in our investigations.17
Immune annotations are also consistently enriched but to
a lesser degree for AD (with involvement from both the
innate and adaptive immune systems), and some cell-spe-
cific immune annotations (T cells) were significantly
enriched for PD. A lack of results from the ALS dataset
could be attributed to this dataset being smaller than the
other datasets investigated (Table 1). These results pro-
vide further support for the neuroinflammatory hypothe-
sis of neurodegenerative disease,15,16 and highlight the
potential utility of immune modulating agents, such as
those currently used in MS for the treatment of AD and
PD. However, one needs to be cautious with interpreting
these cell/tissue-type-specific results in the absence of
functional and other studies.
We note that if we correct for the 17 GWASs assessed in
Finucane et al.31 as well as the four GWASs we assessed
here for the 10 cell-type groups ([17 + 4] 9 10 = 210
hypotheses tested), both the immune/hematopoietic and
liver categories remain significant for AD.
The role of the immune system in AD pathogenicity has
been previously shown22,25 and previous pathway analysis
of the AD GWAS we assessed here showed enrichment in
immune-related pathways.24 Findings are strongest for the
innate immune response, for instance association with the
TREM2 gene, which in brain cells are primarily expressed
on microglia.45,46 Our findings further support the role of
immune variation in AD susceptibility. Interestingly, using
LD score regression, AD was found to be not significantly
correlated with a variety of immune diseases.34 This lack of
correlation could be because when considering the entire
genome the signal coming from the correlated loci between
the diseases is diluted, or the immune variants involved in
AD are different from those involved in other immune dis-
eases. Microglia, the main immune cell type in the brain,
have a different developmental trajectory separate from the
peripheral immune system.47
The unique mechanisms of immune surveillance in the
brain48,49 also make immune diseases of the brain biologi-
cally distinct to peripheral immune diseases, but there is
much evidence that disruption of the brain’s immune
surveillance is critical to the “vicious cycle” of worsening
pathology seen in neurodegeneration.50 Our analysis sug-
gests a predominantly epigenomic mechanism for
immune dysregulation in neurodegenerative disease, and
if confirmed this may be of therapeutic relevance, as
many drugs are known to act through this mechanism.
Some, such as histone deacetylase inhibitors, could poten-
tially be efficacious in neurodegenerative diseases.51
Functional marks from liver were also enriched for the
heritability of AD. This result agrees with findings in the
literature of the contribution of lipid metabolism through
liver X receptors (LXR) to the initiation and progression
of this disease.52,53
Canonical pathway analysis showed enrichment of AD
associations in CREB signaling in neurons, and also IL8
and IL12 signaling (which are CREB regulated), supporting
the immune hypothesis in AD, and pointing to interleukin
signaling as a potential CREB-responsive mechanism.54
Our results do not provide statistically significant evi-
dence that variants overlapping with functional annota-
tions from the brain contribute excessively to the
heritability of neurodegenerative diseases. The brain
doubtless plays an important role in the genetic etiology
of these diseases. The lack of brain annotation enrichment
could be due to data being based on few samples for the
brain. Furthermore, the brain is a very heterogeneous tis-
sue. Data from brain regions contain a mixture of differ-
ent cell types such as microglia and neurons. Single-cell
sampling may reduce this heterogeneity in the future.55
This analysis should be revisited as brain annotation
information improves.
In summary, our results suggest a significant contribu-
tion of variants that exhibit chromatin accessibility marks
in immune cells to the heritability of two neurodegenera-
tive diseases, namely AD and PD.
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Supporting Information
Additional Supporting Information may be found online
in the supporting information tab for this article:
Table S1. Annotation enrichment results. Red cells mark
enrichment that survived Bonferroni correction.
Table S2. Overlap among chromatin accessibility annota-
tions for immune cells. The main diagonal shows genome
coverage (base pairs) for that cell type. The upper off-
diagonal shows the overlap coverage (base pairs) for that
cell-type pair. The lower off-diagonal shows the propor-
tion of overlap coverage for that cell-type pair.
Table S3. (A) Ingenuity Pathway Analysis (IPA) results
for canonical pathways. Red cells mark enrichment that
survived Bonferroni correction. (B) Ingenuity Pathway
Analysis (IPA) results for cancer-related functions. Red
cells mark enrichment that survived Bonferroni correc-
tion. (C) enrichr KEGG pathway results. Multiplication of
the P-value computed using the Fisher’s exact test with
the z-score of the deviation from the expected rank as
described in the enrichr paper.38
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